Effect of inhaled budesonide therapy in term newborns with meconium aspiration syndrome
DOI:
https://doi.org/10.18203/2349-3291.ijcp20231838Keywords:
Comparative study, Respiratory distress, Interventional, Budesonide, SepsisAbstract
Background: Meconium aspiration syndrome is a common cause of respiratory distress in neonates. This study explores the possibility of altering the course of the disease by using anti-inflammatory agents to counter the chemical and inflammatory pneumonitis caused by meconium. The objective is to determine if inhaled budesonide therapy can alter the clinical course of the disease and improve outcome without causing any serious adverse effects.
Methods: A comparative study was conducted in NICU of Cheluvamba hospital, Mysore over 12 months. Neonates with MAS were divided into interventional and control groups. Interventional group received budesonide nebulization 12th hourly starting after 6 hours of life, while control group received saline nebulization 12 hourly. Data was analysed by SPSS 20 software and student t test and chi square test were used to assess statistical significance.
Results: The patient profile of the two groups was similar, with the interventional group showing early normalization of Downes score compared to controls. The duration of respiratory distress, oxygen dependency, and duration of hospital stay was significantly less in the steroid treated group compared to controls. There was no significant difference in the incidence of sepsis between the two groups, and three patients died during hospital stay due to pneumothorax with overwhelming sepsis with DIC.
Conclusions: Nebulized budesonide improves clinical outcome in terms of morbidity and is relatively safe, however long term follow up required to recommend inhalational steroids as safe and effective.
References
Antonowiez I, Schwachman H. Meconium in health and disease. Adv Paediatr. 1979;26:275–310.
Fanaroff AA. Meconium aspiration syndrome: historical aspects. J Perinatol. 2008;28(3):S3-7.
Cleary GM, Wiswell TE. Meconium-stained amniotic fluid and the meconium aspiration syndrome: an update. Pediatr Clin North Am. 1998;45(3)511-29.
Fischer C, Rybakowski C, Ferdynus C, Sagot P, Gouyon JB. A population -based study of meconium aspiration syndrome in neonates born between 37- and 43-weeks gestation. Int J Pediatr. 2012;321545.
Bhutani VK. Developing a systems approach to prevent meconium aspiration syndrome: lessons learned from multinational studies. J Perinatol. 2008;28(3):S30-5.
Poggi SH, Ghidini A. Pathophysiology of meconium passage into the amniotic fluid. Early Hum Dev. 2009;85(10):607-10.
Sankhyan N, Sharma VM. Predictors of meconium stained amniotic fluid: a possible strategy to reduce neonatal morbidity and mortality. J Obstet Gynecol India. 2006;56(6):514-7.
Dargaville PA, Copnell B. Australian and New Zealand Neonatal Network. The epidemiology of meconium syndrome: incidence, risk factors, therapies and outcome. Pediatrics. 2006;117(5):1712-21.
Wiswell TE. Delivery room management of the meconium-stained newborn. J Perinatol. 2008;28(3):S19-26.
Gelfand SL, Fanaroff JM, Walsh MC. Meconium stained fluid: approach to the mother and baby. Pediatr Clin North Am. 2004;51(3):655-67.
Liu WF, Harrington T. Delivery room risk factors for meconium aspiration syndrome. Am J of Perinatol. 2002;19(7):367-78.
Usta IM, Mercer BM, Sibai BM. Risk factors for meconium aspiration syndrome. Obstetgynecol. 1995;86(2):230-34.
Yoder BA, Kirsch EA, Barth WH, Gordon MC. Changing obstetric practices associated with decreasing incidence of meconium aspiration syndrome. Obstet Gynecol. 2002;99(5):731-9.
Ballard RA, Hansen TN, Corbet A. Respiratory failure in the term infant. In: Taeusch HW, Ballard RA, Gleason CA, editors. Avery’s Diseases of the Newborn. 8th ed. Philadelphia: Elsevier Inc. 2005:705-22.
Manning FA, Harman CR, Morrison I, Menticoglou SM, Lange IR, Johnson JM. Fetal assessment based on fetal biophysical profile scoring. Am J Obstet Gynecol. 1990;162(3):703-9.
Richey SD, Ramin SM, Bawson RE. Markers of acute and chronic asphyxia in infants with meconium-stained amniotic fluid. Am J Obstet Gynecol. 1995;172:1212-5.
Ciftci AO, Tanyel FC, Karnak I, Büyükpamukçu N, Hiçsönmez A. In utero defecation: fact or fiction? Eur J Pediatr Surg. 1999;9(6):376-80.
Blackwell SC, Moldenhauer J, Hassan SS, et al. Meconium aspiration syndrome in term neonates with normal acid-base status at delivery: is it different? Am J Obstet Gynecol. 2001;184(7):1422-5.
Ghidini A Spong CY. Severe meconium aspiration syndrome is not caused by aspiration of meconium. Am J Obstet Gynecol. 2001;185(4):931-8.
Kopincova J, Calkovska A. Meconium-induced inflammation and surfactant inactivation: specifics of molecular mechanisms. Pediatr Res. 2016;79(4):514-8.
Zagariya A, Bhat R, Navale S, Vidyasagar D. Cytokine expression in meconium-induced lungs. Indian J Pediatr. 2004;71(3):195-201.
Kojima T, Hattori K, Fujiwara T, Sasai-Takedatsu, M, Kobayashi Y. Meconium induced lung injury mediated by activation of alveolar macrophages. Life Sci. 1994;54(21):1559-62.
Lindenskov PH, Castellheim A, Saugstad OD, Mollnes TE. Meconium aspiration syndrome: possible pathophysiological mechanisms and future potential therapies. Neonatology. 2015;107(3):225-30.
Hofer N, Jank K, Strenger V, Pansy J, Resch B. Inflammatory indices in meconium aspiration syndrome. Pediatr Pulmon. 2016;51(6): 601-6.
Molnes TE, Castellheim A, Lindenskov PH, Salvesen B, Saugstad O. Role of complement in meconium aspiration syndrome. J Perinatol. 2008;28(3):S116-9.
Ahanya SN, Sureshbabu N, Morgan BL, Ross MG. Meconium passage in utero: mechanisms, consequences and management. Obstet Gynecol Surv. 2005;60(1):45-56.
